Literature DB >> 7945331

In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol.

E Lupo1, R Locher, B Weisser, W Vetter.   

Abstract

The dose-dependent (1, 5, 10, 50 microM) antioxidative activity of calcium antagonists (verapamil, diltiazem, nifedipine, amlodipine, isradipine or lacidipine) and alpha-tocopherol against copper-induced LDL (0.25 mg/ml) oxidation was compared by measuring the diene formation and the content of TBARS. For diltiazem no antioxidant effect could be found, whereas the other calcium antagonists and alpha-tocopherol have demonstrated antioxidant activity at least at concentrations of 10 and 50 microM: alpha-tocopherol > lacidipine > nifedipine > isradipine, verapamil, amlodipine. Additionally, alpha-tocopherol and lacidipine were able to attenuate LDL-oxidation significantly at 1 and 5 microM. These results indicate in vitro antioxidative activity of calcium antagonists especially from the dihydropyridine-type with greatest activity for the strongly lipophilic lacidipine. This might be one possible antiatherogenic mechanism of calcium antagonists, since oxidative modification enhances the atherogenic potential of LDL.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945331     DOI: 10.1006/bbrc.1994.2396

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Nicanartine improves in vitro resistance of lipoproteins to oxidation.

Authors:  E Dailly; S Urien; P Wülfroth; J P Tillement
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

3.  Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals.

Authors:  C Napoli; M Chiariello; G Palumbo; G Ambrosio
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

4.  Wound healing potential of topical amlodipine in full thickness wound of rabbit.

Authors:  Ali Asghar Hemmati; Hoda Mojiri Forushani; Hossein Mohammad Asgari
Journal:  Jundishapur J Nat Pharm Prod       Date:  2014-06-16

Review 5.  Perspectives and challenges of antioxidant therapy for atrial fibrillation.

Authors:  Iveta Gasparova; Peter Kubatka; Radka Opatrilova; Martin Caprnda; Slavomira Filipova; Luis Rodrigo; Leone Malan; Ioana Mozos; Miroslava Rabajdova; Vladimir Nosal; Nazarii Kobyliak; Vanda Valentova; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-29       Impact factor: 3.000

Review 6.  Antihypertensive drugs and reversing of endothelial dysfunction in hypertension.

Authors:  S Taddei; A Virdis; L Ghiadoni; I Sudano; A Salvetti
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 7.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

Review 8.  Lipid peroxidation and decomposition--conflicting roles in plaque vulnerability and stability.

Authors:  Sampath Parthasarathy; Dmitry Litvinov; Krithika Selvarajan; Mahdi Garelnabi
Journal:  Biochim Biophys Acta       Date:  2008-03-25

Review 9.  1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative Stress.

Authors:  Astrida Velena; Neven Zarkovic; Koraljka Gall Troselj; Egils Bisenieks; Aivars Krauze; Janis Poikans; Gunars Duburs
Journal:  Oxid Med Cell Longev       Date:  2016-01-06       Impact factor: 6.543

10.  Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction.

Authors:  Anil Kumar; Jitendriya Mishra; Kanwaljit Chopra; Dinesh K Dhull
Journal:  Psychopharmacology (Berl)       Date:  2015-10-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.